Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects With Notalgia Paresthetica

NCT05978063 is registered in ClinicalTrials.gov with Cara Therapeutics, Inc. as lead sponsor.

NCT NCT05978063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05978063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects With Notalgia Paresthetica
Lead sponsor
Cara Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
August 1, 2023
Completion date
May 7, 2024
Enrollment
214 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

notalgia paresthetica, pruritus